236 related articles for article (PubMed ID: 30303876)
21. Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases.
Hentzen JEKR; van der Plas WY; Kuipers H; Ramcharan S; Been LB; Hoogwater FJH; van Ginkel RJ; van Dam GM; Hemmer PHJ; Kruijff S
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):590-599. PubMed ID: 31806520
[TBL] [Abstract][Full Text] [Related]
22. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.
Hallam S; Tyler R; Price M; Beggs A; Youssef H
BJS Open; 2019 Oct; 3(5):585-594. PubMed ID: 31592510
[TBL] [Abstract][Full Text] [Related]
24. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
[TBL] [Abstract][Full Text] [Related]
25. Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Dietz MV; Hannink G; Said I; van der Zant FA; van de Vlasakker VCJ; Brandt-Kerkhof ARM; Verhoef C; Bremers AJA; de Wilt JHW; Hemmer PHJ; de Hingh IHJT; de Reuver PR; Madsen EVE
Eur J Surg Oncol; 2024 Jun; 50(6):108294. PubMed ID: 38583215
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study.
Hammoudi N; Eveno C; Lambert J; Maillet M; Glehen O; Goere D; Lourenco N; Allez M; Aparicio T; Pocard M; Gornet JM;
Eur J Surg Oncol; 2018 Jun; 44(6):799-804. PubMed ID: 29650418
[TBL] [Abstract][Full Text] [Related]
27. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
28. The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases.
Flood MP; Jain A; Mitchell C; Hewitt C; Ramsay R; Michael M; Heriot AG; Tie J
Eur J Surg Oncol; 2022 Oct; 48(10):2218-2225. PubMed ID: 35750576
[TBL] [Abstract][Full Text] [Related]
29. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
30. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
31. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
33. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
34. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study.
Mehta S; Schwarz L; Spiliotis J; Hsieh MC; Akaishi EH; Goere D; Sugarbaker PH; Baratti D; Quenet F; Bartlett DL; Villeneuve L; Kepenekian V;
Eur J Surg Oncol; 2018 Nov; 44(11):1786-1792. PubMed ID: 29885982
[TBL] [Abstract][Full Text] [Related]
35. A critical look at local-regional management of peritoneal metastasis.
Chan CH; Cusack JC; Ryan DP
Hematol Oncol Clin North Am; 2015 Feb; 29(1):153-8. PubMed ID: 25475577
[TBL] [Abstract][Full Text] [Related]
36. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.
Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spilioitis J; Torres-Melero J; Turaga K; Trout R
Ann Surg Oncol; 2014 Dec; 21(13):4195-201. PubMed ID: 24854493
[TBL] [Abstract][Full Text] [Related]
37. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
38. Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis.
Ahmed S; Stewart JH; Shen P; Votanopoulos KI; Levine EA
J Surg Oncol; 2014 Oct; 110(5):575-84. PubMed ID: 25164477
[TBL] [Abstract][Full Text] [Related]
39. Management of colorectal cancer patients at high risk of peritoneal metastases.
Shariff U; Seretis C; Youssef H
J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
[TBL] [Abstract][Full Text] [Related]
40. Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis.
Sun T; Li K; Xu G; Zhu K; Wang Q; Dang C; Yuan D
World J Surg Oncol; 2021 Jul; 19(1):200. PubMed ID: 34229721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]